• Researcher Profile

    Edwin P. Alyea, III, MD

     
    Edwin P. Alyea, III, MD

    Top Doctor

     
    Associate Director, Stem Cell Transplantation
    Director, Oncology Hospital Medicine
    Institute Physician


    Associate Professor of Medicine, Harvard Medical School

    Center/Program

    Hematologic Oncology

    Office phone: 617-632-3903
    Fax: 617-632-5175
    Email: edwin_alyea@dfci.harvard.edu

    Preferred contact method: appointment phone

    View Physician Profile
     
     

    Research Department

    Medical Oncology/Hematologic Malignancies

    Interests

    Stem cell/ bone marrow transplant, Leukemia, Multiple myeloma, Myelodysplasia

    Area of Research

    Adoptive Immunotherapy

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 1B09
    Boston, MA 02215

    Biography

    Dr. Alyea received his MD from Duke University in 1989. He completed postgraduate training in internal medicine at Brigham and Women's Hospital, followed by a fellowship in medical oncology and hematology at DFCI and BWH. In 1996, he joined DFCI, where he currently is a member of the bone marrow transplant staff. His research centers on adoptive immunotherapy for the treatment of hematologic diseases.

    Research

    Adoptive Immunotherapy

    Allogeneic bone marrow transplantation is curative for some patients with hematologic malignancies. Evidence suggests that the success of transplant is related not only to high doses of chemotherapy and radiation but also to the donor's immune system and whether it mediates an antileukemia effect, termed the graft-versus-leukemia (GVL) effect.

    Our group is currently exploring clinical methods to induce the GVL effect after bone marrow transplant. We have demonstrated that by infusing selected donor CD4+ lymphocytes, we can maintain the antileukemia activity while reducing the incidence of graft-versus-host disease. We are now conducting studies using donor dendritic cells in donor lymphocyte infusion (DLI) in an attempt to improve the response to DLI.

    We are also exploring nonmyeloablative transplantation strategies to establish a platform for adoptive immunotherapy. These "mini-transplants" allow allogeneic transplantation to be performed with much less toxicity - permitting patients of more advanced age or with other medical conditons to undergo transplantation. In addition, we are conducting studies focused on augmenting GVL after mini-transplantation.

View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now